5-year Follow-up of a Randomized Controlled Trial of Immediate versus Delayed Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women with Breast Cancer Starting Letrozole after Tamoxifen: N03CC (Alliance)

BACKGROUND: Postmenopausal women with breast cancer (BC) receiving aromatase inhibitors are at increased risk for bone loss. The current study was undertaken to determine whether upfront versus delayed treatment with zoledronic acid (ZA) impacted bone loss. This report describes the 5-year follow-up...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer
Huvudupphovsmän: Wagner-Johnston, Nina D., Sloan, Jeff A., Liu, Heshan, Kearns, Ann E., Hines, Stephanie L., Puttabasavaiah, Suneetha, Dakhil, Shaker R., Lafky, Jacqueline M., Perez, Edith A., Loprinzi, Charles L.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4512885/
https://ncbi.nlm.nih.gov/pubmed/25930719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29327
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk